Used in targeted cancer therapy, particularly for tumors with KRAS G12C mutations. Shows high selectivity in inhibiting the mutated KRAS protein, which is commonly found in non-small cell lung cancer, colorectal cancer, and other solid tumors. Its ability to covalently bind to the inactive form of KRAS G12C helps block downstream signaling pathways involved in cell proliferation and survival. Currently under clinical investigation for efficacy and safety, demonstrating promising antitumor activity in patients with advanced cancers who have limited treatment options.